[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JP2022078208A5 - - Google Patents

Download PDF

Info

Publication number
JP2022078208A5
JP2022078208A5 JP2022033576A JP2022033576A JP2022078208A5 JP 2022078208 A5 JP2022078208 A5 JP 2022078208A5 JP 2022033576 A JP2022033576 A JP 2022033576A JP 2022033576 A JP2022033576 A JP 2022033576A JP 2022078208 A5 JP2022078208 A5 JP 2022078208A5
Authority
JP
Japan
Prior art keywords
host cell
seq
nucleic acid
acid sequence
vector genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022033576A
Other languages
English (en)
Other versions
JP2022078208A (ja
JP7483774B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2018/019996 external-priority patent/WO2018160585A2/en
Application filed filed Critical
Publication of JP2022078208A publication Critical patent/JP2022078208A/ja
Publication of JP2022078208A5 publication Critical patent/JP2022078208A5/ja
Application granted granted Critical
Publication of JP7483774B2 publication Critical patent/JP7483774B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

  1. (a) AAV 5’末端逆位反復(ITR)、発現制御配列に機能可能に繋げられたSMN1タンパク質をコードする核酸配列、及びAAV 3'ITRを含む、ベクターゲノムを含む核酸配列;
    (b) 配列番号8をコードするAAVhu68カプシド核酸配列(AAVhu68 VP1);
    (c) AAV repタンパク質をコードする核酸配列;及び
    (d) ベクターゲノムの複製およびベクターゲノムのAAVhu68カプシド中へのパッケージングを可能にするヘルパー機能、
    を含む宿主細胞。
  2. SMN1タンパク質をコードする核酸配列が、
    (i) 配列番号1か、又は配列番号2のアミノ酸配列のSMN1タンパク質アイソフォームDタンパク質をコードする配列番号1と少なくとも70%同一である配列;
    (ii) 配列番号3;
    (iii) 配列番号4;
    (iv) 配列番号5、又は
    (v) 配列番号6、
    から選択される、請求項1に記載の宿主細胞。
  3. 発現制御配列(a)が、エンハンサー、プロモーター、イントロン、コザック配列、ポリA、又は翻訳後調節要素の1以上を更に含む、請求項1に記載の宿主細胞。
  4. プラスミドが(a)の核酸配列を含む、請求項1に記載の宿主細胞。
  5. プラスミドが(b)及び(c)の核酸配列を含む、請求項1に記載の宿主細胞。
  6. 配列番号8をコードする核酸配列が、配列番号7であるか又はそれと70%同一の配列である、請求項1に記載の宿主細胞。
  7. 宿主細胞が培養物中にある、請求項1に記載の宿主細胞。
  8. 宿主細胞が懸濁液中にある、請求項1に記載の宿主細胞。
  9. 宿主細胞が哺乳動物細胞である、請求項1に記載の宿主細胞。
  10. 宿主細胞がHEK293細胞である、請求項1に記載の宿主細胞。
  11. 宿主細胞が昆虫細胞である、請求項1に記載の宿主細胞。
  12. 請求項1~11のいずれか1に記載の宿主細胞を用いて産生される、SMN1コード配列を含むベクターゲノムを含む組換えアデノ随伴ウイルス(rAAV)hu68ベクター。
  13. ベクターゲノムが、5'AAV ITR、サイトメガロウイルス即時早期エンハンサー、とニワトリベータアクチンプロモーター、イントロン、ポリA、及び3’AAV ITRを含む、請求項11に記載のrAAV。
  14. ベクターゲノムが配列番号15又は配列番号25の配列を有する、請求項11に記載のrAAV。
  15. AAVhu68が、配列番号7又はそれと99%同一である配列を用いて産生される、請求項11~13のいずれか1に記載のrAAV。
JP2022033576A 2017-02-28 2022-03-04 脊髄性筋萎縮症の治療に有用な組成物 Active JP7483774B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762464756P 2017-02-28 2017-02-28
US62/464,756 2017-02-28
US201762515902P 2017-06-06 2017-06-06
US62/515,902 2017-06-06
US201862618437P 2018-01-17 2018-01-17
US62/618,437 2018-01-17
PCT/US2018/019996 WO2018160585A2 (en) 2017-02-28 2018-02-27 Compositions useful in treatment of spinal muscular atrophy
JP2019547087A JP7037574B2 (ja) 2017-02-28 2018-02-27 脊髄性筋萎縮症の治療に有用な組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019547087A Division JP7037574B2 (ja) 2017-02-28 2018-02-27 脊髄性筋萎縮症の治療に有用な組成物

Publications (3)

Publication Number Publication Date
JP2022078208A JP2022078208A (ja) 2022-05-24
JP2022078208A5 true JP2022078208A5 (ja) 2023-01-25
JP7483774B2 JP7483774B2 (ja) 2024-05-15

Family

ID=61800665

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019547087A Active JP7037574B2 (ja) 2017-02-28 2018-02-27 脊髄性筋萎縮症の治療に有用な組成物
JP2022033576A Active JP7483774B2 (ja) 2017-02-28 2022-03-04 脊髄性筋萎縮症の治療に有用な組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019547087A Active JP7037574B2 (ja) 2017-02-28 2018-02-27 脊髄性筋萎縮症の治療に有用な組成物

Country Status (19)

Country Link
US (2) US11578341B2 (ja)
EP (1) EP3589739A2 (ja)
JP (2) JP7037574B2 (ja)
KR (1) KR102697086B1 (ja)
CN (1) CN110741089B (ja)
AU (1) AU2018227442B2 (ja)
BR (1) BR112019016444A2 (ja)
CA (1) CA3055619A1 (ja)
CL (1) CL2019002473A1 (ja)
CO (1) CO2019009522A2 (ja)
IL (1) IL268519B2 (ja)
JO (1) JOP20190200A1 (ja)
MA (1) MA47688A (ja)
MX (1) MX2019010276A (ja)
PE (1) PE20191261A1 (ja)
PH (1) PH12019550149A1 (ja)
SA (1) SA519402566B1 (ja)
SG (2) SG11201907474UA (ja)
WO (1) WO2018160585A2 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102712926B1 (ko) 2016-10-20 2024-10-07 상가모 테라퓨틱스, 인코포레이티드 파브리병의 치료를 위한 방법 및 조성물
MX2019010275A (es) 2017-02-28 2019-10-15 Univ Pennsylvania Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este.
MX2020008932A (es) * 2018-02-27 2020-10-01 Univ Pennsylvania Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos.
JP2022517174A (ja) * 2018-12-21 2022-03-07 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 導入遺伝子発現のdrg特異的低減のための組成物
BR112021012249A2 (pt) * 2019-01-04 2021-09-08 Sangamo Therapeutics, Inc. Métodos e composições para o tratamento da doença de fabry
WO2021183469A1 (en) * 2020-03-09 2021-09-16 Amprion, Inc. Cerebrospinal fluid assay control solution
CA3177407A1 (en) 2020-05-12 2021-11-18 James M. Wilson Compositions for drg-specific reduction of transgene expression
RU2742837C1 (ru) * 2020-06-02 2021-02-11 Общество С Ограниченной Ответственностью "Анабион" Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок SMN1, и ее применение
WO2022028472A1 (en) * 2020-08-05 2022-02-10 Hangzhou Jiayin Biotech Ltd. Nucleic acid constructs and uses thereof for treating spinal muscular atrophy
JP2024505257A (ja) 2021-02-01 2024-02-05 レジェンクスバイオ インコーポレーテッド 神経セロイドリポフスチン症の遺伝子治療
CN112852882A (zh) * 2021-02-04 2021-05-28 中吉智药(南京)生物技术有限公司 一种杆状病毒感染昆虫细胞生产aav基因药物的系统及方法
CN118119710A (zh) * 2021-10-15 2024-05-31 上海天泽云泰生物医药有限公司 用于治疗脊髓性肌萎缩的重组腺相关病毒载体
WO2023087019A2 (en) 2021-11-15 2023-05-19 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
CN114177346B (zh) * 2021-12-24 2023-05-26 中国人民解放军军事科学院军事医学研究院 一种止血组合物及止血贴与其应用
WO2024165839A1 (en) * 2023-02-06 2024-08-15 Royal Holloway And Bedford New College Transgenes
CN118045206B (zh) * 2024-04-12 2024-07-05 四川至善唯新生物科技有限公司 一种治疗脊髓型肌肉萎缩的药物组合物及其用途

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
EP0682717A4 (en) 1993-02-05 1997-04-23 Laporte Group Australia ANTI-FOAMING COMPOSITE FOR DAIRY.
US6972193B1 (en) 1993-02-12 2005-12-06 Board Of Trustees Of Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
US6140120A (en) 1993-02-12 2000-10-31 Board Of Trustees Of Leland Stanford Jr. University Regulated transcription of targeted genes and other biological events
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
ATE453709T1 (de) 1993-02-12 2010-01-15 Univ Leland Stanford Junior Regulierte transkription von zielgerichteten genen und andere biologische ereignisse
US20020173474A1 (en) 1993-02-12 2002-11-21 President And Fellows Of Harvard College Methods & materials involving dimerization-mediated regulation of biological events
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
US6476200B1 (en) 1994-06-27 2002-11-05 The Johns Hopkins University Mammalian proteins that bind to FKBP12 in a rapamycin-dependent fashion
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
DE69534300T2 (de) 1994-08-18 2006-05-18 Ariad Gene Therapeutics, Inc., Cambridge Neues multimerisierendes reagenz
US6150527A (en) 1994-08-18 2000-11-21 Ariad Pharmaceuticals, Inc. Synthetic multimerizing agents
US6133456A (en) 1994-08-18 2000-10-17 Ariad Gene Therapeutics, Inc. Synthetic multimerizing agents
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US6326166B1 (en) 1995-12-29 2001-12-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
JP3817739B2 (ja) 1994-12-29 2006-09-06 マサチューセッツ・インスティテュート・オブ・テクノロジー キメラdna結合性タンパク質
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
US6506379B1 (en) 1995-06-07 2003-01-14 Ariad Gene Therapeutics, Inc. Intramuscular delivery of recombinant AAV
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
ATE465149T1 (de) 1996-02-28 2010-05-15 Ariad Pharma Inc Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen
US6723531B2 (en) 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
EP1591541B1 (en) 1997-04-01 2012-02-15 Illumina Cambridge Limited Method of nucleic acid sequencing
ES2224375T3 (es) 1997-04-14 2005-03-01 Cell Genesys, Inc. Metodos para aumentar la eficacia del producto de aav recombinante.
JP2003524368A (ja) 1997-08-26 2003-08-19 アリアド ジーン セラピューティクス インコーポレイテッド ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、dna結合ドメインまたはリガンド結合ドメインを含む融合蛋白
US6479653B1 (en) 1997-08-26 2002-11-12 Ariad Gene Therapeutics, Inc. Compositions and method for regulation of transcription
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
EP1003886A1 (en) 1997-08-27 2000-05-31 Ariad Gene Therapeutics, Inc. Chimeric transcriptional activators and compositions and uses related thereto
JP2002508971A (ja) 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド 多量体キメラ蛋白質を使用する生物学的イベントの調節
JP2002503667A (ja) 1998-02-13 2002-02-05 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 新規な二量体化剤、その製造および使用
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
EP1080218A1 (en) 1998-05-27 2001-03-07 University of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
US6258603B1 (en) 1998-06-17 2001-07-10 Rohm And Haas Company Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US6210892B1 (en) 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US7109317B1 (en) 1998-11-06 2006-09-19 President And Fellows Of Harvard College FK506-based regulation of biological events
WO2000028004A1 (en) 1998-11-10 2000-05-18 The University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
ES2478635T3 (es) 1999-08-09 2014-07-22 Targeted Genetics Corporation Incremento de la expresión de una secuencia de nucleótidos heteróloga monocatenaria de vectores virales recombinantes diseñando la secuencia de modo que forma pares de bases intracatenarios
DE60010098T2 (de) 1999-08-24 2005-03-31 Ariad Gene Therapeutics, Inc., Cambridge 28-epirapaloge
US6780639B1 (en) 1999-08-24 2004-08-24 Universite Libre De Bruxelles Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
JP3961737B2 (ja) 2000-02-29 2007-08-22 株式会社小糸製作所 車両用灯具およびその製造方法
MXPA02009157A (es) 2000-03-22 2004-04-05 Rohm & Haas Nuevo sistema de expresion genetica inducible a base del receptor de ecdisona.
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
AU2001268149B2 (en) 2000-06-01 2005-08-18 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
US9249207B2 (en) 2001-02-20 2016-02-02 Intrexon Corporation Substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system
US7531326B2 (en) 2001-02-20 2009-05-12 Intrexon Corporation Chimeric retinoid X receptors and their use in a novel ecdysone receptor-based inducible gene expression system
MXPA03007493A (es) 2001-02-20 2004-10-15 Rheogene Holdings Inc Nuevo sistema de expresion genetica inducible a base de receptor de ecdisona/receptor x retinoide de invertebrado.
EP2275558B1 (en) 2001-02-20 2018-11-28 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
EP1392868B2 (en) 2001-05-18 2013-09-04 Wisconsin Alumni Research Foundation Method for the synthesis of dna sequences using photo-labile linkers
DE60209193T2 (de) 2001-11-13 2006-09-28 Trustees Of The University Of Pennsylvania Verfahren zur Identifizierung von Adeno-assoziiertem Virus (AAV) Sequenzen sowie Kit zur Ausführung der Methode
PT2359869T (pt) 2001-12-17 2019-04-16 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
WO2003104413A2 (en) 2002-06-05 2003-12-18 University Of Florida Production of pseudotyped recombinant aav virions
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
EP1660970A4 (en) 2003-08-01 2007-02-14 Dna Twopointo Inc SYSTEMS AND METHODS FOR BIOPOLYMER TECHNOLOGY
CN102199626B (zh) 2003-09-30 2015-06-24 宾夕法尼亚大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
US20060246079A1 (en) 2003-11-14 2006-11-02 Morrow Phillip R Neutralizing human antibodies to anthrax toxin
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
ES2525067T3 (es) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Método de incremento de la función de un vector de AAV
WO2006119458A1 (en) 2005-05-02 2006-11-09 Genzyme Corporation Gene therapy for neurometabolic disorders
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
WO2007002390A2 (en) 2005-06-23 2007-01-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing
US8877187B2 (en) 2005-07-25 2014-11-04 Avianax, Llc Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US9198984B2 (en) 2006-04-28 2015-12-01 The Trustees Of The University Of Pennsylvania Scalable production method for AAV
MX364444B (es) 2006-06-07 2019-04-26 Genzyme Corp Terapia génica para esclerosis lateral amiotrófica y otros trastornos de la médula espinal.
SI3146982T1 (sl) 2006-10-03 2019-11-29 Genzyme Corp Genska terapija za amiotrofično lateralno sklerozo in druge motnje hrbtenjače
EP2126105A4 (en) 2007-02-20 2010-11-03 Anaptysbio Inc SOMATIC HYPERPERMUTATION SYSTEMS
WO2008110937A2 (en) 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus
US9217020B2 (en) 2007-04-17 2015-12-22 National Research Council Of Canada Constructs for enhancement of gene expression in muscle
US7879326B2 (en) 2007-06-15 2011-02-01 The Board Of Trustees Of The Leland Stanford Junior University Human neutralizing monoclonal antibodies to H5N1 influenza A virus
US8057796B2 (en) 2007-11-12 2011-11-15 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2009079259A2 (en) 2007-12-06 2009-06-25 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
EP2274334A2 (en) 2008-03-28 2011-01-19 Sea Lane Biotechnologies,llc. Neutralizing molecules to viral antigens
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
WO2010044921A2 (en) 2008-06-03 2010-04-22 Vaxin Inc. Intranasal administration of receptor-binding ligands or genes encoding such ligands as a therapeutic regimen for mitigating infections caused by respiratory pathogens
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
NZ590890A (en) 2008-07-25 2013-05-31 Inst Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US8211631B2 (en) 2008-12-18 2012-07-03 Wisconsin Alumni Research Foundation In vitro model of spinal muscular atrophy
RS62779B1 (sr) 2009-05-02 2022-01-31 Genzyme Corp Genska terapija neurodegenerativnih poremećaja
SG176003A1 (en) 2009-05-11 2011-12-29 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
HUE039741T2 (hu) 2009-06-17 2019-01-28 Biogen Ma Inc Készítmények és módszerek az SMN2 splicing módosítására egy alanynál
AU2010266078B2 (en) 2009-06-25 2014-08-14 Medimmune, Llc Swine influenza hemagglutinin variants
US8598331B2 (en) 2009-09-28 2013-12-03 The University Of British Columbia CLDN5 mini-promoters
AU2011238708B2 (en) 2010-03-29 2016-02-11 The Trustees Of The University Of Pennsylvania Pharmacologically Induced Transgene Ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
WO2012145572A1 (en) 2011-04-20 2012-10-26 The Trustees Of The University Of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
WO2012145759A2 (en) 2011-04-21 2012-10-26 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Methods of protein production and compositions thereof
KR20240135871A (ko) 2011-06-08 2024-09-12 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
MX346206B (es) 2011-07-14 2017-03-09 Crucell Holland Bv Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b.
WO2013114885A1 (en) 2012-01-31 2013-08-08 Osaka University Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same
KR102050615B1 (ko) 2012-03-08 2019-11-29 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 b 바이러스들에 결합하고 중화할 수 있는 인간 결합 분자 및 그 용도
WO2013151663A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
WO2013155222A2 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Brain-specific enhancers for cell-based therapy
SG11201406776TA (en) 2012-04-18 2015-03-30 Philadelphia Children Hospital Composition and methods for highly efficient gene transfer using aav capsid variants
BR112014029807A2 (pt) 2012-06-08 2017-06-27 Ethris Gmbh administração pulmonar de rna mensageiro
EP2864488A1 (en) 2012-06-21 2015-04-29 Association Institut de Myologie Widespread gene delivery of gene therapy vectors
PL2880053T3 (pl) 2012-08-01 2021-01-11 Ikaika Therapeutics, Llc Łagodzenie uszkodzenia tkanek i włóknienia przez przeciwciało przeciwko ltbp4
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
CA2911105A1 (en) * 2013-05-01 2014-11-06 Genzyme Corporation Compositions and methods for treating spinal muscular atrophy
MX2016001026A (es) 2013-07-26 2016-08-03 Univ Iowa Res Found Metodos y composiciones para tratar enfermedades del cerebro.
EA201690588A1 (ru) * 2013-10-22 2016-09-30 Шир Хьюман Дженетик Терапис, Инк. Доставка мрнк в цнс и ее применение
EP3060669A1 (en) 2013-10-24 2016-08-31 uniQure IP B.V. Aav-5 pseudotyped vector for gene therapy for neurological diseases
CA2939200A1 (en) 2014-02-19 2015-08-27 Jody Berry Ebola monoclonal antibodies
US10780182B2 (en) 2014-04-25 2020-09-22 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
US11555059B2 (en) 2014-04-25 2023-01-17 The Trustees Of The University Of Pennsylvania LDLR variants and their use in compositions for reducing cholesterol levels
US10746742B2 (en) * 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
EA034355B1 (ru) 2014-05-02 2020-01-30 Джензим Корпорейшн Векторы на основе aav для генной терапии в сетчатке и cns
MY186389A (en) 2014-05-13 2021-07-22 Univ Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof
PL3198018T3 (pl) 2014-09-24 2021-07-19 City Of Hope Warianty wektora wirusa związanego z adenowirusami dla wysokiej skuteczności edycji genomu i jego sposoby
AU2015327819B2 (en) 2014-10-03 2021-07-01 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
KR20170107562A (ko) 2015-02-05 2017-09-25 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 적혈구응집소에 대한 결합 분자 및 이의 용도
EA201792500A1 (ru) 2015-05-13 2018-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Aav-опосредованная экспрессия антител против гриппа и способы их использования
CN108779167A (zh) 2015-10-28 2018-11-09 宾夕法尼亚州大学信托人 鞘内施用腺伴随病毒载体用于基因治疗
EP3387138B1 (en) 2015-12-11 2022-01-26 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
ES2918998T3 (es) 2015-12-11 2022-07-21 Univ Pennsylvania Método de purificación escalable para AAVrh10
WO2017100674A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav1
EP3387117B1 (en) 2015-12-11 2022-11-23 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
WO2017106326A1 (en) 2015-12-14 2017-06-22 The Trustees Of The University Of Pennsylvania Aav-anti pcsk9 antibody constructs and uses thereof
AU2016370630B2 (en) 2015-12-14 2023-04-13 The Trustees Of The University Of Pennsylvania Adeno-associated viral vectors useful in treatment of spinal muscular atropy
US20190002915A1 (en) 2015-12-14 2019-01-03 The Trustees Of The University Of Pennsylvania Compositions and methods for regulatable antibody expression
SG11201806270XA (en) 2016-02-03 2018-08-30 Univ Pennsylvania Gene therapy for treating mucopolysaccharidosis type i
KR102425289B1 (ko) 2016-08-15 2022-07-27 젠자임 코포레이션 Aav의 검출 방법
US20190240328A1 (en) 2016-09-24 2019-08-08 The Trustees Of The University Of Pennsylvania Novel humanized anti-ebola antibodies useful in preventing ebola infections
MX2019010275A (es) 2017-02-28 2019-10-15 Univ Pennsylvania Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este.
EP3589649A1 (en) 2017-02-28 2020-01-08 The Trustees Of The University Of Pennsylvania Influenza vaccines based on aav vectors

Similar Documents

Publication Publication Date Title
JP2022078208A5 (ja)
US7851195B2 (en) High-efficiency wild-type-free AAV helper functions
CN109715650B (zh) 新颖腺相关病毒衣壳蛋白
JP7140830B2 (ja) Aav粒子の産生を目的としたベクター
US6365403B1 (en) High-efficiency AAV helper functions
CA2236968C (en) Accessory functions for use in recombinant aav virion production
JP5364903B2 (ja) 昆虫細胞におけるaavの生成に有用なaav−rep78の翻訳の改変型開始コドンを有するベクター
JP2023093577A (ja) 昆虫細胞における向上したaavカプシド産生
US7125705B2 (en) Polynucleotides for use in recombinant adeno-associated virus virion production
JP2022060228A5 (ja)
CA2228269C (en) High efficiency helper system for aav vector production
JP2023519502A (ja) Aav生成のための二重二官能基ベクター
AU2003272672B2 (en) High titer recombinant AAV production
JP7530431B2 (ja) Dna増幅方法
JPWO2021067448A5 (ja)
EP4263575A1 (en) Adeno-associated virus capsids and vectors
CN118414348A (zh) 经修饰的aav衣壳和载体
JPWO2021076911A5 (ja)
JPWO2022076803A5 (ja)
RU2779318C2 (ru) Новые капсидные белки адено-ассоциированного вируса
JPWO2021080991A5 (ja)
JP2024517104A (ja) Careエレメントを用いたdna増幅方法
JPWO2021221995A5 (ja)
WO2024121778A1 (en) Improved rep genes for recombinant aav production
RU2022111734A (ru) Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови VIII c делетированным B доменом, и ее применение